-

12:39:43 AM

FWBI Stock News

FWBI - First Wave BioPharma Inc

01/13/22 7:00 AM

Nasdaq : FWBI

low float

First Wave BioPharma Provides Update on Adrulipase (FW-EPI) Clinical Program

Company filed two provisional patent applications for new enteric granule formulation of adrulipase and for related nutritional indications in new patient populations “Adrulipase Alfa” approved by World Health Organization (WHO) as International Nonproprietary Name (INN) Initiation of adrulipase

RHEA-AI

neutral

01/07/22 9:16 AM

Nasdaq : FWBI

low float

First Wave BioPharma Announces Further Adjournment of Annual Meeting

First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today

RHEA-AI

neutral

01/06/22 7:00 AM

Nasdaq : FWBI

clinical trialcovid-19low float

First Wave BioPharma Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections

First Wave BioPharma, Inc.,

RHEA-AI

neutral

01/04/22 7:00 AM

Nasdaq : FWBI

conferenceslow float

First Wave BioPharma to Participate in Two Investor Conferences in January 2022

First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the

RHEA-AI

neutral

12/17/21 9:06 AM

Nasdaq : FWBI

low float

First Wave BioPharma Announces Adjournment of Annual Meeting

First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today

RHEA-AI

neutral

12/13/21 7:00 AM

Nasdaq : FWBI

low float

First Wave BioPharma Chairman and CEO Issues Letter to Shareholders

First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today

RHEA-AI

neutral

12/09/21 7:00 AM

Nasdaq : FWBI

managementlow float

First Wave BioPharma Names Brian Feagan, M.D., to Scientific Advisory Board

First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or

RHEA-AI

neutral

12/06/21 7:00 AM

Nasdaq : FWBI

conferenceslow float

First Wave BioPharma’s CEO and President, James Sapirstein, to Participate in CEO Panel Discussion at 2021 BioFlorida Conference

First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the

RHEA-AI

neutral

11/30/21 7:00 AM

Nasdaq : FWBI

clinical trialcovid-19low float

First Wave BioPharma Announces Independent Data Monitoring Committee Provides Positive Interim Safety Assessment for Part 2 COVID-19 RESERVOIR Clinical Trial of Niclosamide for the Treatment of Gastrointestinal Infections

First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of

RHEA-AI

neutral

11/16/21 7:00 AM

Nasdaq : FWBI

acquisitionlow float

First Wave BioPharma Announces Restructuring of Merger Consideration Payment Terms With Former Shareholders of First Wave Bio

First Wave BioPharma, Inc. (NASDAQ:FWBI), (“First Wave BioPharma,” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today

RHEA-AI

positive

FWBI Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.azurrx.com
CeoJames Sapirstein
Security nameFirst Wave BioPharma Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees12
Address760 Parkside Ave Ste 304
StateNew York
CityBrooklyn
Zip11226-1784
CountryUS
Phone16466997855

FWBI Description:

AzurRx BioPharma, Inc. is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI assets. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, FW-420, for grade 1 Immune Checkpoint Inhibitor Colitis and diarrhea in oncology patients and FW-1022, for COVID-19 gastrointestinal infections. The Company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California.